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Abstract
Background: Xpert MTB/RIF has been shown to have a superior sensitivity to microscopy for acid fast bacilli (AFB)
in sputum and has been recommended as a standard first line investigation for pulmonary tuberculosis (PTB).
Bronchoscopy is a valuable tool in diagnosing PTB in sputum negative patients. There is limited data on the utility
of Xpert MTB/RIF performed on bronchial lavage specimens. Our aim was to evaluate the diagnostic efficiency of
Xpert MTB/RIF performed on bronchial washings in sputum scarce/negative patients with suspected PTB.
Methods: All patients with a clinical and radiological suspicion of PTB who underwent bronchoscopy between
January 2013 and April 2014 were included. The diagnostic efficiencies of Xpert MTB/RIF and microscopy for AFB
were compared to culture for Mycobacterium tuberculosis.
Results: Thirty nine of 112 patients were diagnosed with culture-positive PTB. Xpert MTB/RIF was positive in 36/39
with
a sensitivity of 92.3 % (95 % CI 78–98 %) for PTB, which was superior to that of smear microscopy (41 %; 95 % CI
26.0–57.8 %, p = 0.005). The specificities of Xpert MTB/RIF and smear microscopy were 87.7 % (95 % CI 77.4–93.9 %)
and 98.6 % (95 % CI 91.6 %–99.9 %) respectively. Xpert MTB/RIF had a positive predictive value of 80 % (95 % CI;
65–89.9 %) and negative predictive value of 95.5 % (95 % CI 86.6–98.8 %). 3/9 patients with Xpert MTB/RIF positive
culture negative results were treated for PTB based on clinical and radiological findings.
Conclusion: Xpert MTB/RIF has a higher sensitivity than smear microscopy and similar specificity for the immediate
confirmation of PTB in specimens obtained by bronchial washing, and should be utilised in patients with a high
suspicion of pulmonary tuberculosis.
Background
Early diagnosis and treatment of pulmonary tubercu-
losis is essential in reducing the spread, morbidity, mor-
tality and the escalating costs associated with advanced
disease [1]. Microbiological confirmation of Mycobac-
terium tuberculosis disease can be challenging in pa-
tients with a low bacterial load or in those who do not
expectorate. Bronchoscopy with washings, with or
without biopsy, can aid diagnosis by providing adequate
samples for testing [2, 3].
Most of the evidence confirming the utility of the
newly WHO endorsed Xpert MTB/RIF has been based
on studies performed on sputum samples [4, 5]. The re-
ported sensitivity of 90.4 % is significantly higher than
that of smear microscopy, which is around 28 % [4, 6].
Recent studies have also suggested that Xpert MTB/RIF’s
sensitivity is not affected by HIV status [4, 7]. There is
limited data validating the routine use of Xpert MTB/
RIF on bronchial lavages, as the majority of cohorts
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contained low numbers of patients from whom bron-
chial lavages were obtained [4, 7–9].
The aim of this study was to evaluate the diagnostic
efficiency of Xpert MTB/RIF performed on bronchial
washing fluid obtained bronchoscopically from patients
with a clinical and radiological suspicion of pulmonary
tuberculosis.
Methods
Study population
We screened all smear negative/sputum scarce patients
who underwent bronchoscopy as part of their work up for
suspected pulmonary tuberculosis at Tygerberg Academic
Hospital and Kuils River Hospital during the period from
January 2013 to April 2014, and retrospectively included
all patients with complete sets of medical, radiological and
laboratory data. Tygerberg Academic Hospital is a tertiary
hospital in Cape Town, South Africa. It is one of two re-
ferral centres and it renders a tertiary service to a popula-
tion of approximately 3.6 million people. Kuilsrivier
Hospital is a secondary hospital in Cape Town, offering
private health care to patients. For the purposes of our
study we considered a clinical suspicion of pulmonary tu-
berculosis if any two of the following were present: known
HIV infection, persistent cough lasting > 3 weeks, haem-
optysis, weight loss > 4 kg, intermittent fever > 3 weeks or
drenching night sweats > 2 weeks. In addition, at least one
of the following radiological criteria had to be present for
inclusion: cavitation, diffuse infiltrates, hilar or mediastinal
adenopathy. The study was approved by the Health
Research Ethics Committee of Stellenbosch University
(S13/04/063). A waiver of consent was approved due to
the retrospective nature of the study.
Bronchoscopy procedure
Flexible bronchoscopies were performed in dedicated
suites under conscious sedation. Washings were ob-
tained by instilling 10 ml of 0.9 % saline into a segment
of an affected lobe and aspirating available fluid (re-
peated three times). Transbronchial biopsies and trans-
bronchial needle aspiration of lymph nodes were
performed at the discretion of the endoscopist.
Microbiology
Samples were processed according to standard laboratory
protocols by decontamination with N-acetyl-L-cysteine/
NaOH, centrifugation and fluorescent microscopy for acid
fast bacilli [10]. Decontaminated samples were inoculated
in the BACTEC MGIT culture system, (Becton Dickinson,
Sparks, Maryland, USA) and incubated for 6 weeks [11].
Positive cultures were identified as M. tuberculosis and
tested for susceptibility to rifampicin and isoniazid using
the MTBDRplus line probe assay (Hain LifeSciences,
Nehren, Germany).
All Xpert MTB/RIF samples were processed accord-
ing to the manufacturer’s specifications [12]. Bronchial
washing fluid was incubated, without prior decontam-
ination, with sample reagent in a cartridge and loaded
within 30 min of preparation. A test was positive if
Mycobacterium tuberculosis was identified within 38 cy-
cles [13]. Xpert MTB/RIF generated results (cycle
threshold values) were categorised as either high posi-
tive (< 16), medium (16–21), low (22–28) or very low
positive (> 28) [12].
Diagnosis of pulmonary tuberculosis
We use a positive culture of Mycobacterium tubercu-
losis as the gold standard for the diagnosis of pulmon-
ary tuberculosis in our primary analysis. In a secondary
analysis, we also included cases with histological or
cytological features of caseating granuloma containing
acid fast bacilli, or cases where at least three clinical
and one radiological criterion were present in a patient
who subsequently showed documented clinical and
radiological improvement after six months of anti-
tuberculosis treatment (despite negative microbiology).
Statistical analysis
Descriptive statistics were performed and a composite
reference standard used. Analyses were conducted of
data collected per patient. The sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) of Xpert MTB/RIF were calculated using
standard methods and Xpert MTB/RIF generated re-
sults (cycle threshold values) listed. Unless stated
otherwise, data is displayed as means and standard de-
viation (SD).
Results
Patients
We screened 184 patients with suspected pulmonary tu-
berculosis during the study period, and included 112 pa-
tients (age 44.4 +/− 15.9 years, 54 males) with complete
records (Fig. 1). A total of 132 lobes were sampled in
these patients.
A total of 44 patients were ultimately treated for pul-
monary tuberculosis, based on positive culture (n = 39),
histological or cytological features (n = 2) and on clinical
and radiological grounds with clinical response to treat-
ment (n = 3). Alternative diagnoses for the remaining 68
patients are summarised in Fig. 1.
Radiographic features observed in the study popula-
tion included cavitatory disease (n = 12), consolidation
(n = 24), diffuse nodular infiltrates (n = 13), alveolar infil-
trates (n = 35), pulmonary mass lesions (n = 13), pleural
effusions (n = 9) and isolated lymphadenopathy (n = 6).
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Microbiology
Xpert MTB/RIF was positive in 36 of the 39 confirmed
cases, compared to smear microscopy that was positive in
16. Only one case of isoniazid mono-resistance was identi-
fied in the 39 cases who were culture positive, with no
cases of Rifampicin resistance. The sensitivities, specific-
ities, PPVs and NPVs for culture, microscopy and Xpert
MTB/RIF are summarised in Table 1. Xpert MTB/RIF had
a sensitivity of 92.3 % (95 % CI 78–98 %) for PTB, which
was superior to that of smear microscopy (41 %; 95 % CI
26–57.8 %, p = 0.005). The specificities of Xpert MTB/RIF
and smear microscopy were 87.7 % (95 % CI 77.4–93.9 %)
and 98.6 % (95 % CI 91.6 %–99.9 %) respectively. The
diagnostic efficiency of Xpert MTB/RIF was 89.3 %. Cycle
threshold values for the patients diagnosed with PTB
varied between high positive (n = 8), medium (n = 12), low
(n = 11), and very low positive (n = 5).
Nine Xpert MTB/RIF positive, culture negative cases
were identified (Table 2). Of these, the majority had very
low positive Xpert MTB/RIF results (n = 7) and only
three were ultimately treated for suspected pulmonary
tuberculosis.
Discussion
In this study, performed in a population with a high pre-
test probability for pulmonary tuberculosis, we found
Xpert MTB/RIF to have a sensitivity, specificity and
negative predictive value of around 90 %, and a positive
predictive value of approximately 80 %. Xpert MTB/RIF
had a very high diagnostic efficiency of 89.3 %. The ma-
jority of Xpert MTB/RIF positive, culture negative
results were observed in cases with very low positive
Xpert MTB/RIF results and a past history of pulmonary
tuberculosis.
Patients screened (n=184) 
Patients included (n=112) Patients excluded due to incomplete data (n=72) 
Treated as pulmonary tuberculosis (n=44) Pulmonary tuberculosis excluded, alternative diagnoses made (n=68) 
TB Culture positive (n=39) Histology / Clinical / Radiological 
diagnosis (n=5)
Xpert MTB/RIF positive (n=6) Xpert MTB/RIF negative (n=62)
Xpert MTB/RIF 
positive (n=36)
Xpert MTB/RIF 
negative (n=3) 
Xpert MTB/RIF 
positive (n=3)
Xpert MTB/RIF 
negative (n=2) 
Bronchiectasis             (n
Pneumonia                  (n
Sarcoidosis                  (n=5)
MOT (n=2)
Other                            (n
=17)
Malignancy (n=13)
=13)
=12)
Previous TB    (n=2)
Malignancy     (n=2)
Uncertain        (n=2) 
Fig. 1 Patients flow through the study. MOT Mycobacterium other than tuberculosis
Table 1 Sensitivity, specificity, positive predictive value and negative predictive value of culture, microscopy and Xpert MTB/RIF
performed on lavage specimens
Smear Microscopy Xpert MTB/RIF Adjusted Xpert MTB/RIFa
% 95 % CI % 95 % CI % 95 % CI
Sensitivity 41.0 26 – 57.8 92.3 78 – 98 88.6 74.6 – 95.7
Specificity 98.6 91.6 – 99.9 87.7 77.4 – 93.9 91.2 81.1 – 96.4
PPV 94.1 69.2 – 99.7 80.0 64.9 – 89.9 86.7 72.5 – 94.4
NPV 75.8 65.7 – 83.7 95.5 86.6 – 98.8 92.5 82.7 – 97.2
95 % CI 95 % confidence interval, PPV positive predictive value, NPV negative predictive value
aSecondary analysis (including cases diagnosed on clinical, histological and radiological means)
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The sensitivity observed in the present study is on par
with sensitivities recently reported in two studies (ran-
ging from 82–93 %), but the specificity is marginally
lower than the reported 96–100 % [7, 8]. The studies re-
ported by Lee et al. and Theron et al. included similar
numbers of patients diagnosed with pulmonary tubercu-
losis, and utilised comparable diagnostic criteria for the
diagnosis of pulmonary tuberculosis [7, 8].
We identified 9 cases of Xpert MTB/RIF positive cul-
ture, negative cases, of which three were treated for pul-
monary tuberculosis. Current evidence suggests that
pulmonary tuberculosis treatment within the preceding
5 years can potentially RIF/RIF [14, 15]. Up to 27 % of
patients have been reported to remain sputum Xpert
MTB/RIF positive 26 weeks after successful anti-
tuberculous treatment was initiated [16, 17]. Due to the
nature of the polymerase chain reaction test, Xpert
MTB/RIF amplifies any DNA whether it originates
from alive or dead bacilli. Therefore it cannot be as-
sumed, solely on the basis of the test, that a positive re-
sult equates to active disease [12, 18]. It is also unclear
whether the bacterial load in bronchoscopy samples in
patients with latent infection or recent exposure would
reach this limit and potentially result in a very low posi-
tive Xpert MTB/RIF test result. More evidence is
needed on the interpretation of Xpert MTB/RIF in the
setting of recently treated tuberculosis, which may be
the most important cause of false positive results.
No cross-reactivity has been reported between Xpert
MTB/RIF and multiple bacteria, viruses, fungi or myco-
bacteria species other than tuberculosis and should there-
fore not be the reason for false positive results [19, 20].
We observed a single case of false positive Xpert MTB/
RIF in a patient with confirmed Mycobacterium avium
intracellulare infection. It is likely that dual pathology (in-
cluding undiagnosed previous tuberculosis) and laboratory
contamination may have been present in this case, as well
as the other cases not treated as pulmonary tuberculosis, a
finding that has been reported in similar settings with a
high HIV prevalence [21-23].
It should be noted that 7 of the 9 Xpert MTB/RIF posi-
tive culture negative cases had very low positive test results.
Some correlation between Xpert MTB/RIF generated
quantitative information and bacterial load and disease se-
verity has been described [21, 22]. Xpert MTB/RIF’s calcu-
lated analytical limit of detection has been reported as
131 cfu/ml (95% CI 106.2–176.4). The relationship between
Xpert MTB/RIF generated cycle threshold values, bacterial
load and smear microscopy grades has shown that very low
positive test results (cycle threshold values >28 cycles) cor-
relate with negative microscopy and low positive values
(22–28) with scanty positive smear microscopy [7, 21, 22].
This also correlated to the lower end of time-to-positivity
of cultures. More research is required to aid in the inter-
pretation of Xpert MTB/RIF with very low positive results,
which in clinical practice, may be interpreted in the same
light as a negative or, at best, scanty positive smear micros-
copy result. Our observations suggest that very low positive
results require confirmation by culture or other means in
cases with a low pre-test probability. Cut-off values for
positivity should potentially vary between high and low en-
demic tuberculosis areas with lower cycle threshold values
accepted as positive in high endemic areas. Moreover, clini-
cians practicing in high burden settings should be aware
that past tuberculosis and dual pathology should be consid-
ered in cases with unexpected positive Xpert MTB/RIF.
The present study has several limitations. The retro-
spective nature limited the data collection to cases with
complete clinical, radiological and microbiological data,
and precluded any analyses on the excluded patient
population. Some cases with false negative cultures may
have gone undetected, and the true sensitivity may be
different. We were also not able to document the true
impact of Xpert MTB/RIF performed on bronchial la-
vages on the time to diagnosis or treatment, which is ar-
guably of even greater clinical relevance.
Table 2 Xpert MTB/RIF positive, culture negative cases
Case Previous PTB Ct value Treated for PTB Alternative diagnoses/comments
1 Unknown Low Yes Confirmed pleural tuberculosis
2 No Very low Yes Takayashu’s arteritis
3 Unknown Very low Yes Clinical response to PTB treatment
4 Yes Medium No Surveillance bronchoscopy to exclude bronchial stenosis 1 year after PTB
5 Yes Very low No Repeat bronchoscopy culture and Xpert MTB/RIF negative
6 Unknown Very low No Squamous cell carcinoma of the lung
7 No Very low No Squamous cell carcinoma of the lung
8 No Very low No Symptoms resolved with treatment
9 Yes Very low No Culture positive for Mycobacterium avium intracellulare
PTB pulmonary tuberculosis, Ct value cycle threshold value
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Conclusion
Xpert MTB/RIF has a higher sensitivity than smear mi-
croscopy and similar specificity for the immediate con-
firmation of pulmonary tuberculosis on specimens
obtained from bronchial washing, and should routinely be
utilised in patients with a high clinical suspicion of pul-
monary tuberculosis. Positive Xpert MTB/RIF, culture
negative results should be interpreted in the clinical con-
text, and ideally be confirmed with additional tests and/or
follow-up.
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